RSS feed

Publications by Jan Oldenburg

74 publications found

Original articles

Woods SS, Oldenburg J, van Leeuwen D, Sarasohn-Kahn J, Hudson MF (2023)
An Extraordinary Voice Expressed Through Humor: A Tribute to Casey Quinlan
J Particip Med, 15, e54527
DOI 10.2196/54527, PubMed 38085561

Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N (2023)
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Nat Med, 30 (1), 257-264
DOI 10.1038/s41591-023-02704-x, PubMed 38049622

Albertsen PC, Bjerner LJ, Pasovic L, Müller S, Fosså S, Carlsson SV, Oldenburg J (2023)
Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge
BJU Int, 133 (1), 104-111
DOI 10.1111/bju.16211, PubMed 37869764

van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, Ürün Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD, CheckMate 901 Trial Investigators (2023)
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma
N Engl J Med, 389 (19), 1778-1789
DOI 10.1056/NEJMoa2309863, PubMed 37870949

Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K (2023)
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
Lancet, 402 (10398), 291-303
DOI 10.1016/S0140-6736(23)01055-3, PubMed 37285865

Bamias A, Stenzl A, Brown SL, Albiges L, Babjuk M, Birtle A, Briganti A, Burger M, Choudhury A, Colecchia M, De Santis M, Fanti S, Fonteyne V, Gallucci M, Rivas JG, Huddart R, Junker K, Kroeze S, Loriot Y, Merseburger A, Montironi R, Necchi A, Oing C, Oldenburg J, Ost P et al. (2023)
Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty
Eur Urol, 84 (4), 381-389
DOI 10.1016/j.eururo.2023.05.005, PubMed 37217391

Hussein R, Pichon A, Oldenburg J, Sareban M, Niebauer J (2023)
Can Patient Contributed Data (PCD) Leverage Connected Health Technology for Cardiac Rehabilitation in Austria?
Stud Health Technol Inform, 302, 8-12
DOI 10.3233/SHTI230054, PubMed 37203599

Bjerner J, Bratt O, Aas K, Albertsen PC, Fosså SD, Kvåle R, Lilja H, Müller C, Müller S, Stensvold A, Thomas O, Røe OD, Vickers A, Walz J, Carlsson SV, Oldenburg J (2023)
Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium
Eur Urol (in press)
DOI 10.1016/j.eururo.2023.04.028, PubMed 37169639

Hussein R, Griffin AC, Pichon A, Oldenburg J (2023)
A guiding framework for creating a comprehensive strategy for mHealth data sharing, privacy, and governance in low- and middle-income countries (LMICs)
J Am Med Inform Assoc, 30 (4), 787-794
DOI 10.1093/jamia/ocac198, PubMed 36259962

Karttunen E, Hervonen P, Hosseini Aliabad A, Oldenburg J, Pappot H, Sairanen J, Støvring H, Vásquez JL, Bergman S, Magnussen G, Norremark P, Thoresen S, Ullén A (2022)
Incidence, mortality and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 2019
Scand J Urol, 57 (1-6), 15-21
DOI 10.1080/21681805.2022.2138965, PubMed 36416403

Tahiri A, Puco K, Naji F, Kristensen VN, Alfsen GC, Farkas L, Nilsen FS, Müller S, Oldenburg J, Geisler J (2022)
Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors
Oncotarget, 13, 970-981
DOI 10.18632/oncotarget.28257, PubMed 36093296

De Laere B, Crippa A, Discacciati A, Larsson B, Oldenburg J, Mortezavi A, Ost P, Eklund M, Lindberg J, Grönberg H, ProBio Investigators (2022)
Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer
Eur Urol Focus, 8 (6), 1617-1621
DOI 10.1016/j.euf.2022.03.005, PubMed 35317973

Oldenburg J, Maletzki L, Strohbach A, Bellé P, Siewert S, Busch R, Felix SB, Schmitz KP, Stiehm M (2021)
Methodology for comprehensive cell-level analysis of wound healing experiments using deep learning in MATLAB
BMC Mol Cell Biol, 22 (1), 32
DOI 10.1186/s12860-021-00369-3, PubMed 34078283

Aeppli S, Eboulet EI, Eisen T, Escudier B, Fischer S, Larkin J, Gruenwald V, McDermott D, Oldenburg J, Omlin A, Porta C, Rini B, Schmidinger M, Sternberg C, Rothermundt C (2020)
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
ESMO Open, 5 (Suppl 3)
DOI 10.1136/esmoopen-2020-000852, PubMed 32669298

Crippa A, De Laere B, Discacciati A, Larsson B, Connor JT, Gabriel EE, Thellenberg C, Jänes E, Enblad G, Ullen A, Hjälm-Eriksson M, Oldenburg J, Ost P, Lindberg J, Eklund M, Grönberg H (2020)
The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer
Trials, 21 (1), 579
DOI 10.1186/s13063-020-04515-8, PubMed 32586393

Skalleberg J, Småstuen MC, Oldenburg J, Osnes T, Fosså SD, Bunne M (2020)
The Relationship Between Cisplatin-related and Age-related Hearing Loss During an Extended Follow-up
Laryngoscope, 130 (9), E515-E521
DOI 10.1002/lary.28543, PubMed 32065408

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A et al. (2019)
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort^†: Under the Auspices of the EAU-ESMO Guidelines Committees
Eur Urol, 77 (2), 223-250
DOI 10.1016/j.eururo.2019.09.035, PubMed 31753752

Normann MC, Türzer M, Diep LM, Oldenburg J, Gajdzik B, Solheim O, Rud E (2019)
Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer
J Gynecol Oncol, 30 (4), e56
DOI 10.3802/jgo.2019.30.e56, PubMed 31074244

Hjelle LV, Gundersen POM, Hellesnes R, Sprauten M, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Oldenburg J, Bremnes RM, Haugnes HS (2018)
Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors
Acta Oncol, 57 (10), 1392-1400
DOI 10.1080/0284186X.2018.1473641, PubMed 29775128

Beisland C, Johannesen TB, Klepp O, Axcrona U, Torgersen KM, Kowalski J, Solli O, Sandin R, Oldenburg J (2017)
Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study
Onco Targets Ther, 10, 371-385
DOI 10.2147/OTT.S123061, PubMed 28144152

Oldenburg J, Dieckmann KP (2016)
Contralateral biopsies in patients with testicular germ cell tumours: What is the rationale?
World J Urol, 35 (8), 1161-1166
DOI 10.1007/s00345-016-1945-9, PubMed 27738807

Hjelle LV, Bremnes RM, Gundersen POM, Sprauten M, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Oldenburg J, Haugnes HS (2016)
Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors
Urol Oncol, 34 (11), 487.e13-487.e20
DOI 10.1016/j.urolonc.2016.06.012, PubMed 27523611

Gerwing M, Jacobsen C, Dyshlovoy S, Hauschild J, Rohlfing T, Oing C, Venz S, Oldenburg J, Oechsle K, Bokemeyer C, von Amsberg G, Honecker F (2016)
Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells
J Cancer Res Clin Oncol, 142 (9), 1979-94
DOI 10.1007/s00432-016-2204-6, PubMed 27424191

Dahl AA, Østby-Deglum M, Oldenburg J, Bremnes R, Dahl O, Klepp O, Wist E, Fosså SD (2016)
Aspects of posttraumatic stress disorder in long-term testicular cancer survivors: cross-sectional and longitudinal findings
J Cancer Surviv, 10 (5), 842-9
DOI 10.1007/s11764-016-0529-4, PubMed 26920871

Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, Nicolai N, Oldenburg J, European Association of Urology (2015)
Guidelines on Testicular Cancer: 2015 Update
Eur Urol, 68 (6), 1054-68
DOI 10.1016/j.eururo.2015.07.044, PubMed 26297604

Rothermundt C, Bailey A, Cerbone L, Eisen T, Escudier B, Gillessen S, Grünwald V, Larkin J, McDermott D, Oldenburg J, Porta C, Rini B, Schmidinger M, Sternberg C, Putora PM (2015)
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes
Oncologist, 20 (9), 1028-35
DOI 10.1634/theoncologist.2015-0145, PubMed 26240132

Hjelle LV, Gundersen PO, Oldenburg J, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Bremnes RM, Haugnes HS (2015)
Long-term platinum retention after platinum-based chemotherapy in testicular cancer survivors: a 20-year follow-up study
Anticancer Res, 35 (3), 1619-25
PubMed 25750319

Haugnes HS, Oldenburg J, Bremnes RM (2014)
Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors
Urol Oncol, 33 (9), 399-406
DOI 10.1016/j.urolonc.2014.11.012, PubMed 25554583

Tandstad T, Solberg A, Håkansson U, Stahl O, Haugnes HS, Oldenburg J, Dahl O, Kjellman A, Angelsen A, Cohn-Cedermark G, SWENOTECA (2014)
Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols
Acta Oncol, 54 (4), 493-9
DOI 10.3109/0284186X.2014.953256, PubMed 25192551

Sprauten M, Brydøy M, Haugnes HS, Cvancarova M, Bjøro T, Bjerner J, Fosså SD, Oldenburg J (2014)
Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors
J Clin Oncol, 32 (6), 571-8
DOI 10.1200/JCO.2013.51.2715, PubMed 24419125

Putora PM, Oldenburg J (2013)
Swarm-based medicine
J Med Internet Res, 15 (9), e207
DOI 10.2196/jmir.2452, PubMed 24052454

Fung C, Fossa SD, Milano MT, Oldenburg J, Travis LB (2013)
Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study
J Clin Oncol, 31 (30), 3807-14
DOI 10.1200/JCO.2013.50.3409, PubMed 24043737

Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydøy M, Oldenburg J, Dahl AA, Bremnes RM, Fosså SD (2012)
Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up
J Clin Oncol, 30 (30), 3752-63
DOI 10.1200/JCO.2012.43.4431, PubMed 23008318

Daneshmand S, Albers P, Fosså SD, Heidenreich A, Kollmannsberger C, Krege S, Nichols C, Oldenburg J, Wood L (2012)
Contemporary management of postchemotherapy testis cancer
Eur Urol, 62 (5), 867-76
DOI 10.1016/j.eururo.2012.08.014, PubMed 22938868

Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, Beard C, Haugnes HS, Fosså SD, Oldenburg J, Travis LB (2011)
Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer
J Clin Oncol, 30 (3), 300-7
DOI 10.1200/JCO.2011.37.4025, PubMed 22184390

Stephenson AJ, Aprikian AG, Gilligan TD, Oldenburg J, Powles T, Toner GC, Waters WB (2011)
Management of low-stage nonseminomatous germ cell tumors of testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009
Urology, 78 (4 Suppl), S444-55
DOI 10.1016/j.urology.2011.02.030, PubMed 21986224

Oldenburg J, Lorch A, Fosså SD (2011)
Late relapse of germ cell tumors
Hematol Oncol Clin North Am, 25 (3), 615-26, x
DOI 10.1016/j.hoc.2011.03.006, PubMed 21570613

Fosså SD, Cvancarova M, Chen L, Allan AL, Oldenburg J, Peterson DR, Travis LB (2011)
Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients
J Clin Oncol, 29 (8), 963-70
DOI 10.1200/JCO.2010.32.3204, PubMed 21300926

Brydøy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Hauge ER, Dahl O, Fosså SD (2009)
Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors
J Natl Cancer Inst, 101 (24), 1682-95
DOI 10.1093/jnci/djp413, PubMed 19940282

Oldenburg J, Fosså SD (2009)
Late relapse of nonseminomatous germ cell tumours
BJU Int, 104 (9 Pt B), 1413-7
DOI 10.1111/j.1464-410X.2009.08868.x, PubMed 19840022

Fosså SD, Oldenburg J, Dahl AA (2009)
Short- and long-term morbidity after treatment for testicular cancer
BJU Int, 104 (9 Pt B), 1418-22
DOI 10.1111/j.1464-410X.2009.08869.x, PubMed 19840023

Kraggerud SM, Oldenburg J, Alnaes GI, Berg M, Kristensen VN, Fossa SD, Lothe RA (2009)
Functional glutathione S-transferase genotypes among testicular germ cell tumor survivors: associations with primary and post-chemotherapy tumor histology
Pharmacogenet Genomics, 19 (10), 751-9
DOI 10.1097/FPC.0b013e3283304253, PubMed 19741569

Skaali T, Fosså SD, Bremnes R, Dahl O, Haaland CF, Hauge ER, Klepp O, Oldenburg J, Wist E, Dahl AA (2009)
Fear of recurrence in long-term testicular cancer survivors
Psychooncology, 18 (6), 580-8
DOI 10.1002/pon.1437, PubMed 18855944

Oldenburg J, Kraggerud SM, Brydøy M, Cvancarova M, Lothe RA, Fossa SD (2007)
Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study
J Transl Med, 5, 70
DOI 10.1186/1479-5876-5-70, PubMed 18162130

Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD (2007)
Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors
J Clin Oncol, 25 (6), 708-14
DOI 10.1200/JCO.2006.08.9599, PubMed 17228018

Oldenburg J, Fosså SD, Dahl AA (2006)
Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors
Qual Life Res, 15 (5), 791-800
DOI 10.1007/s11136-005-5370-6, PubMed 16721639

Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD (2003)
Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses
J Clin Oncol, 21 (17), 3310-7
DOI 10.1200/JCO.2003.03.184, PubMed 12947067

Review articles

Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, van Leenders GJLH, Liew M, Linares Espinos E, Oldenburg J, van Oort IM, Oprea-Lager DE, Ploussard G, Roberts MJ, Rouvière O, Schoots IG et al. (2024)
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent
Eur Urol (in press)
DOI 10.1016/j.eururo.2024.03.027, PubMed 38614820

Slevin F, Zattoni F, Checcucci E, Cumberbatch MGK, Nacchia A, Cornford P, Briers E, De Meerleer G, De Santis M, Eberli D, Gandaglia G, Gillessen S, Grivas N, Liew M, Linares Espinós EE, Oldenburg J, Oprea-Lager DE, Ploussard G, Rouvière O, Schoots IG, Smith EJ, Stranne J, Tilki D, Smith CT, Van Den Bergh RCN et al. (2023)
A Systematic Review of the Efficacy and Toxicity of Brachytherapy Boost Combined with External Beam Radiotherapy for Nonmetastatic Prostate Cancer
Eur Urol Oncol (in press)
DOI 10.1016/j.euo.2023.11.018, PubMed 38151440

Patrikidou A, Cazzaniga W, Berney D, Boormans J, de Angst I, Di Nardo D, Fankhauser C, Fischer S, Gravina C, Gremmels H, Heidenreich A, Janisch F, Leão R, Nicolai N, Oing C, Oldenburg J, Shepherd R, Tandstad T, Nicol D (2023)
European Association of Urology Guidelines on Testicular Cancer: 2023 Update
Eur Urol, 84 (3), 289-301
DOI 10.1016/j.eururo.2023.04.010, PubMed 37183161

Kaufmann E, Antonelli L, Albers P, Cary C, Gillessen Sommer S, Heidenreich A, Oing C, Oldenburg J, Pierorazio PM, Stephenson AJ, Fankhauser CD (2022)
Oncological Follow-up Strategies for Testicular Germ Cell Tumours: A Narrative Review
Eur Urol Open Sci, 44, 142-149
DOI 10.1016/j.euros.2022.08.014, PubMed 36106144

Williams SB, Ray-Zack MD, Hudgins HK, Oldenburg J, Trinh QD, Nguyen PL, Shore ND, Wirth MP, O'Brien T, Catto JWF (2018)
Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review
Eur Urol Oncol, 2 (3), 265-273
DOI 10.1016/j.euo.2018.10.006, PubMed 31200840

Boormans JL, Mayor de Castro J, Marconi L, Yuan Y, Laguna Pes MP, Bokemeyer C, Nicolai N, Algaba F, Oldenburg J, Albers P (2017)
Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel
Eur Urol, 73 (3), 394-405
DOI 10.1016/j.eururo.2017.09.025, PubMed 29100813

Oldenburg J (2015)
Hypogonadism and fertility issues following primary treatment for testicular cancer
Urol Oncol, 33 (9), 407-12
DOI 10.1016/j.urolonc.2015.01.014, PubMed 25736189

Oldenburg J, Wahlqvist R, Fosså SD (2009)
Late relapse of germ cell tumors
World J Urol, 27 (4), 493-500
DOI 10.1007/s00345-009-0411-3, PubMed 19373473

Oldenburg J, Fosså SD, Ikdahl T (2008)
Genetic variants associated with cisplatin-induced ototoxicity
Pharmacogenomics, 9 (10), 1521-30
DOI 10.2217/14622416.9.10.1521, PubMed 18855538

Oldenburg J, Lehne G, Fosså SD (2008)
[Testicular cancer]
Tidsskr Nor Laegeforen, 128 (4), 457-60
PubMed 18274581

Oldenburg J, Martin JM, Fosså SD (2006)
Late relapses of germ cell malignancies: incidence, management, and prognosis
J Clin Oncol, 24 (35), 5503-11
DOI 10.1200/JCO.2006.08.1836, PubMed 17158535

Other articles

Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N (2024)
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Nat Med (in press)
DOI 10.1038/s41591-024-02835-9, PubMed 38297094

Karttunen E, Oldenburg J, Thoresen S, Ullén A (2023)
Response to M. Brehmer: Register-based research. Accurate data and analysis, crucial for correct conclusions. Comment on 'Incidence, mortality, and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 2019'
Scand J Urol, 58, 20
DOI 10.2340/sju.v58.10299, PubMed 37260404

Fankhauser CD, Oldenburg J, Albers P, Algaba F, Bokemeyer C, Boormans JL, Fischer S, Fizazi K, Gremmels H, Mayor de Castro J, Janisch F, Muilwijk T, Leão R, Nicol D, Nicolai N, Tandstad T, Pilar Laguna M (2021)
Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021
Eur Urol, 80 (1), 4-6
DOI 10.1016/j.eururo.2021.02.032, PubMed 33722419

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van Der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A et al. (2020)
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]
Eur Urol, 78 (1), e48-e50
DOI 10.1016/j.eururo.2020.03.017, PubMed 32446863

Heinrich D, Russnes KM, Oldenburg J (2018)
Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Eur Urol, 74 (2), 236-237
DOI 10.1016/j.eururo.2018.04.010, PubMed 29691083

Oldenburg J, Gietema JA (2016)
The Sound of Silence: A Proxy for Platinum Toxicity
J Clin Oncol, 34 (23), 2687-9
DOI 10.1200/JCO.2016.68.2476, PubMed 27382103

Oldenburg J, Haugnes HS, Dahl O, Karlsdottir Å, Langberg CW, Klepp O, Solberg A, Tandstad T (2015)
[Treatment for stage I-testicular cancer should be assessed individually]
Tidsskr Nor Laegeforen, 135 (15), 1340-1
DOI 10.4045/tidsskr.15.0544, PubMed 26315230

Oldenburg J, de Wit R (2015)
Primum Non Nocere: Of Course! But How?
J Clin Oncol, 33 (20), 2320
DOI 10.1200/JCO.2015.61.2291, PubMed 26033803

Fung C, Fossa SD, Milano MT, Oldenburg J, Travis LB (2014)
Reply to G. Gandaglia et al
J Clin Oncol, 32 (11), 1167-9
DOI 10.1200/JCO.2013.54.6168, PubMed 24590643

Putora PM, Oldenburg J (2014)
The Kafkaesque process of cancer diagnosis
J Clin Oncol, 32 (10), 1087-8
DOI 10.1200/JCO.2013.54.2449, PubMed 24590639

Oldenburg J, Fosså SD (2013)
Testicular cancer in 2013: towards personalized medicine--are we there yet?
Nat Rev Urol, 11 (2), 68-9
DOI 10.1038/nrurol.2013.298, PubMed 24366345

Kersten C, Cameron MG, Oldenburg J (2012)
Truth in hope and hope in truth
J Palliat Med, 15 (1), 128-9
DOI 10.1089/jpm.2011.0209, PubMed 22268412

Oldenburg J, Gietema JA (2010)
It's time to systematically investigate biomarkers for treatment allocation of testicular cancer patients
BJU Int, 107 (6), 942-3
DOI 10.1111/j.1464-410X.2010.10004.x, PubMed 21392209

Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer D, Miller RC, Gietema JA, van Leeuwen FE, Williams JP, Nichols CR, Einhorn LH, Fossa SD (2010)
Testicular cancer survivorship: research strategies and recommendations
J Natl Cancer Inst, 102 (15), 1114-30
DOI 10.1093/jnci/djq216, PubMed 20585105

Christensen K, Oldenburg J (2009)
Giving patients their results online might be the answer
Arch Intern Med, 169 (19), 1816; author reply 1816-7
DOI 10.1001/archinternmed.2009.369, PubMed 19858449

Oldenburg J, Fosså SD (2009)
Exploration of platinum-induced neuropathy should be based on both objective and subjective examinations
Acta Oncol, 48 (6), 804-6
DOI 10.1080/02841860902984729, PubMed 19484592